The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong.
Feature|Articles|September 2, 2026
Redefining Medical Strategy in Obesity Through Real-World iNSIGHTS
Author(s)Lexi Cogswell, PhD, Tom Rotolo, PhD
Real-world evidence tells you what happened. Real-World iNSIGHTS tell you why — and what to do next. A new framework for medical affairs.
Advertisement
Advertisement
As the healthcare community grapples with rising obesity rates, medical strategy generation is undergoing its most significant evolution in decades, moving away from a traditional model of data dissemination toward a future defined by strategic intelligence. To meet the challenges of this complex therapeutic area, pharmaceutical organizations must look beyond traditional data sources and embrace a new way: supporting the generation of Real-World iNSIGHTS.
Related to this article
As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to own the patient journey.
Life sciences liability risks change character — not just size — as companies move from R&D to commercialization.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
Bristol Myers Squibb’s Wendy Short Bartie on recasting corporate affairs as an enterprise value engine that connects trust, access and the patient voice.
Nine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand therapy asset from BoomRay Pharmaceuticals, and Rafaat Rahmani argues that the costliest competitive intelligence failure is missing the moment a strategic assumption goes wrong.
Chairs of Europe's largest drugmakers urge the EU to boost health spending, speed up clinical trials, and strengthen IP protections before falling further behind the US and China.
Novartis has agreed to pay BoomRay up to $900 million for exclusive global rights to an undisclosed preclinical radioligand therapy asset.
Advertisement
Advertisement